目的:目前正在使用汉密尔顿和蒙哥马利-奥斯贝格抑郁量表评估重度抑郁症(MDD)的症状。然而,关于这两种量表的比较研究很少。我们的研究旨在确定汉密尔顿抑郁量表(HDRS)和蒙哥马利-奥斯贝格抑郁量表(MADRS)在12周的基线评分之间的相关性。
方法:正在进行的随机,开放标签,这里描述了三臂研究的中期分析。参与者在基线时使用HDRS和MADRS进行评估,四,八,口服维拉唑酮(20-40mg/d)后12周,艾司西酞普兰(10-20mg/d),或沃替西汀(5-20mg/d)。这项研究在临床试验注册中心进行了前瞻性注册,印度(CTRI/2022/07/043808)。
结果:在71名招募人员中,49人(69%)完成了为期12周的访问。在基线,三组的HDRS评分中位数分别为30.0、29.5和29.0(p=0.76),12周时,它们降低到19.5、19.5和18.0(p=0.18)。在基线,各组MADRS评分中位数分别为36、36和36(p=0.79);12周时,分别为24、24和23(p=0.03)。Pearson相关性显示,艾司西酞普兰(r=0.70,p=0.002)与沃替西汀(r=0.59,p=0.01)和维拉唑酮(r=0.59,p=0.02)的基线评分变化之间的相关性最强。Bland-Altman分析显示,得分之间的平均差为5.11(95%CI:3.08-7.14)。
结论:根据这项中期研究,治疗12周后,HDRS和MADRS评分下降。两个分数都有很强的正相关,分数之间的差异随着时间的推移而减小。
OBJECTIVE: The symptoms of major depressive disorder (MDD) are nowadays being assessed with the Hamilton and Montgomery-Åsberg Depression Rating Scales. However, there are few studies on the comparison of these two scales. Our study aimed to determine the correlation between the Hamilton Depression Rating Scale (HDRS) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores at baseline through 12 weeks.
METHODS: An ongoing randomized, open-label, three-arm study\'s interim analysis is portrayed here. The participants were assessed with HDRS and MADRS at baseline, four, eight, and 12 weeks after receiving oral tablets of either vilazodone (20-40 mg/d), escitalopram (10-20 mg/d), or vortioxetine (5-20 mg/d). This study is prospectively registered with the Clinical Trial Registry, India (CTRI/2022/07/043808).
RESULTS: Of 71 recruited individuals, 49 (69%) completed the 12-week visit. At baseline, the three groups\' median HDRS scores were 30.0, 29.5, and 29.0 (p=0.76), and at 12 weeks, they reduced to 19.5, 19.5, and 18.0 (p=0.18). At baseline, the group-wise median MADRS scores were 36, 36, and 36 (p=0.79); at 12 weeks, they were 24, 24, and 23 (p=0.03). The Pearson correlation revealed that the association between the changes in scores from baseline was strongest for escitalopram (r=0.70, p=0.002) followed by vortioxetine (r=0.59, p=0.01) and vilazodone (r=0.59, p=0.02). The Bland-Altman analysis showed that the mean difference between the scores was 5.11 (95% CI: 3.08-7.14).
CONCLUSIONS: According to this interim study, HDRS and MADRS scores declined after 12 weeks of therapy. Both scores had strong positive correlation, and the difference between the scores reduced with time.